Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 20/20 | 1.00 |
| ▸ | PPARA | Q07869 | 17/20 | 1.00 |
| ▸ | PPARG | P37231 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16553231 | 1.00 | PPARD (1.00) | PPARDPPARAPPARG | |
| SCHEMBL22323851 | 1.00 | PPARD (1.00) | PPARDPPARAPPARG | |
| SCHEMBL29801700 | 1.00 | PPARD (1.00) | PPARDPPARAPPARG | |
| SCHEMBL23752211 | 0.90 | PPARA (1.00) | PPARDPPARAPPARG | |
| SCHEMBL18644833 | 0.90 | PPARA (1.00) | PPARDPPARAPPARG | |
| SCHEMBL6498633 | 0.82 | PPARA (0.86) | PPARDPPARAPPARG | |
| SCHEMBL3418675 | 0.81 | PPARA (0.83) | PPARDPPARAPPARG | |
| SCHEMBL6496446 | 0.80 | PPARA (0.76) | PPARDPPARAPPARG | |
| SCHEMBL3943372 | 0.77 | PPARD (1.00) | PPARDPPARAPPARG | |
| SCHEMBL6374864 | 0.76 | PPARA (1.00) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | WASHINGTON UNIVERSITY | 2022-11-24 | — | — | US | claimed |
| EP-4031124-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | Reneo Pharmaceuticals, Inc. (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | RENEO PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | claimed |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | claimed |
| US-20250360139-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | VTV THERAPEUTICS LLC (US) | 2025-11-27 | — | — | US | disclosed |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | RENEO PHARMACEUTICALS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230233570-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230127775-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | ULTRAGENYX PHARMACEUTICAL INC. | 2023-04-27 | — | — | US | disclosed |
| US-20220387393-A1 | METHODS FOR THE TREATMENT OF DYSMYELINATING/DEMYELINATING DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | WASHINGTON UNIVERSITY | 2022-11-24 | — | — | US | disclosed |
| EP-4031124-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | Reneo Pharmaceuticals, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | RENEO PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220072005-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | VTVX HOLDINGS II LLC | 2022-03-10 | — | — | US | disclosed |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127775-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | GAA, LIPA, TTR | PPARD 3779/4885PPARA 2117/4885PPARG 2661/4885 |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885PPARG 1/4885 |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
| US-20220072005-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885PPARG 2/4885 |
| US-20250360139-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885PPARG 2/4885 |
| US-20230233570-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | PPARD, PPARA, MTPN | PPARD 1/4885PPARA 2/4885PPARG 4/4885 |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | PPARD, ACOX1, CPT1A | PPARD 1/4885PPARA 8/4885PPARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.